About Chiasma
Chiasma is a Healthcare company based in Needham (United States) founded in 2001, and was acquired by Amryt Pharma in May 2021. Therapies for rare diseases are developed via oral platform technology. Its chief executive, as recorded, is Raj Kannan. Its focus areas include Life Sciences, Rare Diseases, Drugs and Metabolic Disorders. Its competitors include Ultragenyx, Alnylam and Gemini Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2001 and headquartered in Needham, United States, operations are focused on the biotechnology sector. Therapies for rare and debilitating diseases are advanced through the proprietary Transient Permeability Enhancer (TPE) platform, enabling oral formulations of medications traditionally administered by injection. The lead candidate, Mycapssa (octreotide capsules), targets acromegaly and has progressed to phase III clinical trials, with company products receiving FDA approval.
- Headquarters Needham, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website chiasma.com
- Social LinkedIn
- Acquired by Amryt Pharma (May 2021)
- Latest Funding Round$10M (USD), Debt – Conventional
Jun 2011
- Investors
- Acquired byAmryt Pharma
(May 2021)
Funding Insights of Chiasma
- Total Rounds 1
- Last Round Debt – Conventional — $10M
- First Round $10M
(Jun 2011)
All 1 funding rounds of Chiasma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2011 | $10M | Debt – Conventional | – | – | – |
1 investors in total: 1 institutional.
Investors in Chiasma
Chiasma has secured backing from 1 investor. Prominent investors backing the company include Amryt Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Therapeutics for rare dermatological and orphan diseases are developed. | 2015 | amrytpharma.com | Dublin, Ireland |
Investor details for Chiasma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Chiasma
1 people are tracked at Chiasma (1 in leadership).
| Name | Role | Group |
|---|---|---|
Raj Kannan | CEO | Leadership |
Complete people profiles for Chiasma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Chiasma
4 dated milestones of Chiasma across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Chiasma is founded.
- Funding First funding round of $10.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Amryt Pharma.
Competitors of Chiasma
Chiasma has 3 listed competitors in our database, 3 of them funded. They include Ultragenyx, Alnylam and Gemini Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| geminitherapeutics.com | 2015 | Cambridge, United States | $44.5M | 45 | Developer of precision therapeutics for dry AMD and rare genetic diseases |
Detailed competitors of Chiasma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Chiasma (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Chiasma
Complete news archive for Chiasma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Chiasma
Chiasma was founded in 2001 and raised its 1st funding round 10 years after it was founded.
Chiasma is headquartered in Needham, United States. It is registered at Needham, Massachusetts, United States.
Raj Kannan is the CEO of Chiasma, as recorded in our data.
Founded in 2001 and headquartered in Needham, United States, operations are focused on the biotechnology sector. Therapies for rare and debilitating diseases are advanced through the proprietary Transient Permeability Enhancer (TPE) platform, enabling oral formulations of medications traditionally administered by injection. The lead candidate, Mycapssa (octreotide capsules), targets acromegaly and has progressed to phase III clinical trials, with company products receiving FDA approval.
Chiasma's top competitors include Alnylam, Ultragenyx and Gemini Therapeutics.
Chiasma has 1 investor. Key investors include Amryt Pharma.
Yes. Chiasma was acquired by Amryt Pharma in May 2021.